Have a question?
Contact us today!

Neurodegenerative Diseases Expertise

Neurodegenerative Diseases Expertise

Experience with Neurodegenerative Indication Research Studies

Neurodegenerative conditions, such as Alzheimer’s and Parkinson’s diseases, remain a significant source of pain for many patients and their caregivers. Our team is well-equipped with operational and medical fundamentals as well as novel approaches to chart a path forward for your therapy.

We have experience with more than 50 studies across a range of neurodegenerative indications and study types:

  • Parkinson’s disease
  • Frontotemporal lobe dementia
  • Alzheimer’s disease (disease modifying and symptomatic)
  • Dementia with Lewy bodies
  • Single-ascending-dose (SAD) and multiple-ascending dose (MAD) trials
  • Radiopharmaceutical
  • Gene therapy

Solutions for Neurodegenerative Clinical Trial Sites and Patient Access

  • PPD-owned clinical research unit in Orlando, Florida, with extensive experience in neurodegenerative disorders
  • Our Synexus HealthMinds Registry
    • Enrolling 30,000+ U.S. participants and facilitating access to prodromal/MCI trial subjects
  • PPD’s SiteCoach training program to support sites new to clinical research
  • Enhanced diversity and collaboration with patient advocacy groups
  • Minimized patient burden

Our Teams Share Your Passion in the Quest Against Neurodegenerative Diseases

Mellissa Cook, Director, Project Management at PPD
Mellissa Cook, Director, Project Management at PPD

“Frontotemporal dementia (FTD) runs through my family, and we look for hope from the pharmaceutical community to change our potential outcome. Working with sponsors to cure neurologic diseases like FTD, Alzheimer’s and Parkinson’s diseases keep me focused on a positive future for all families impacted today.”

Clinical Trial Design for Alzheimer’s Disease with ACE Simulator

Building on widely used models in Alzheimer’s disease, our scientists designed an Alzheimer’s disease archimedes condition event (ACE) simulator to optimize trial design. The ACE simulator is intended to assess interventions from the earliest (i.e., mild cognitive impairment or prodromal Alzheimer’s disease) through the most severe stages of the disease and the transition from normal cognitive function.